ClinicalTrials.gg
Active, not recruitingNCT07940140Updated Nov 16, 2026

Gut Barrier Function and Metabolic Risk in Women With Excessive Gestational Weight Gain

An observational study in Excessive Gestational Weight Gain, sponsored by Cumhuriyet University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Cumhuriyet University · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
80
Ages
18 Years and older
Sex
Female
01

Study summary

This observational cross-sectional study aims to investigate the association of excessive gestational weight gain with intestinal barrier function, metabolic endotoxemia, systemic inflammation, vitamin D/VDR signaling, and insulin resistance in pregnant women with normal pre-pregnancy body mass index (BMI).

The study includes 80 women with singleton pregnancies at ≥37 weeks of gestation, divided into two groups according to the 2009 Institute of Medicine (IOM) gestational weight gain recommendations: excessive gestational weight gain (n=40) and recommended gestational weight gain (n=40).

Serum levels of zonulin, intestinal fatty acid-binding protein (I-FABP), glucagon-like peptide-2 (GLP-2), lipopolysaccharide-binding protein (LBP), soluble CD14 (sCD14), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), vitamin D receptor (VDR), and 25-hydroxyvitamin D [25(OH)D] will be evaluated. The findings may help identify biomarkers associated with maternal metabolic risk.

Read the detailed description

This observational, cross-sectional study is conducted at the Department of Obstetrics and Gynecology, Sivas Cumhuriyet University Faculty of Medicine Hospital, Türkiye. The study includes 80 pregnant women with normal pre-pregnancy BMI (18.5-24.9 kg/m²), singleton pregnancies at ≥37 weeks of gestation, and no known metabolic diseases.

Participants are classified into two groups based on gestational weight gain according to the 2009 Institute of Medicine (IOM) recommendations:

  • Excessive Gestational Weight Gain Group (n=40): Pregnant women whose gestational weight gain exceeds the recommended range.
  • Recommended Gestational Weight Gain Group (n=40): Pregnant women whose gestational weight gain remains within the recommended range.

Maternal demographic, anthropometric, and routine biochemical data are recorded. Blood samples collected from participants are used to evaluate intestinal barrier integrity, metabolic endotoxemia, systemic inflammation, vitamin D/VDR signaling, and insulin resistance.

Serum concentrations of zonulin, I-FABP, and GLP-2 are assessed as intestinal barrier-related biomarkers. LBP and sCD14 are measured as markers associated with metabolic endotoxemia, while TNF-α, IL-6, and hs-CRP are evaluated as inflammatory biomarkers. VDR and 25(OH)D levels are assessed to investigate the potential role of vitamin D signaling in maternal metabolic alterations. Biomarker measurements are performed using commercially available ELISA kits.

Routine biochemical parameters and indicators of insulin resistance are also evaluated. Differences between the two groups and associations among biomarkers, gestational weight gain, and metabolic parameters are analyzed using appropriate statistical methods.

The study aims to investigate whether excessive gestational weight gain is associated with alterations in intestinal barrier-related biomarkers, increased metabolic endotoxemia, systemic inflammation, and insulin resistance, and whether the vitamin D/VDR axis may play a modulatory role in these relationships.

The findings are expected to contribute to understanding the biological mechanisms associated with excessive gestational weight gain and to identifying potential biomarkers of maternal metabolic risk.

02

Conditions studied

  • Excessive Gestational Weight Gain

Keywords

  • Gestational Weight Gain
  • Intestinal Barrier Function
  • Metabolic Endotoxemia
  • Insulin Resistance
  • Vitamin D Receptor
  • Systemic Inflammation
  • Zonulin
  • Maternal Metabolic Risk
03

In context

Gestational Weight Gain

135 studies on the registry are indexed under Gestational Weight Gain; 24 are open to participants now.

This study's enrollment of 80 is below the median of 400 across 23 observational studies indexed under Gestational Weight Gain.

Browse Gestational Weight Gain studies →

Lead sponsor

Cumhuriyet University is the lead sponsor of 135 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of 80 pregnant women with normal pre-pregnancy BMI (18.5-24.9 kg/m²), singleton pregnancies at ≥37 weeks of gestation, and no known metabolic diseases, followed at Sivas Cumhuriyet University Faculty of Medicine Hospital. Participants are classified into two groups according to the 2009 IOM gestational weight gain recommendations: excessive gestational weight gain (n=40) and recommended gestational weight gain (n=40).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women aged 18 years or older.
  • Pre-pregnancy between 18.5 and 24.9 kg/m².
  • Singleton pregnancy at ≥37 weeks of gestation.
  • Gestational weight gain exceeding or within the recommended range according to the 2009 Institute of Medicine (IOM) guidelines.
  • Voluntary participation with written .

Exclusion criteria

Exclusion Criteria:

  • Pre-existing metabolic diseases.
  • Multiple pregnancies.
  • Gestational age below 37 weeks.
  • Pre-pregnancy outside the normal range.
  • Incomplete clinical data or inadequate blood samples for biomarker analysis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
80 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Excessive Gestational Weight Gain Group

    Pregnant women with normal pre-pregnancy BMI (18.5-24.9 kg/m²) and gestational weight gain exceeding the 2009 IOM recommendations (n=40).

  • Recommended Gestational Weight Gain Group (Control Group)

    Pregnant women with normal pre-pregnancy BMI (18.5-24.9 kg/m²) and gestational weight gain within the 2009 IOM recommended range (n=40).

06

What researchers measure

Primary outcomes

  1. Serum Zonulin Level

    Serum zonulin concentrations measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups

    Time frame: At enrollment (≥37 weeks of gestation)

  2. Serum I-FABP Level

    Serum intestinal fatty acid-binding protein (I-FABP) concentrations measured using a commercially available ELISA kit and compared between the two gestational weight gain groups.

    Time frame: At enrollment (≥37 weeks of gestation)

  3. Serum GLP-2 Level

    Serum glucagon-like peptide-2 (GLP-2) concentrations measured using a commercially available ELISA kit and compared between the two gestational weight gain groups.

    Time frame: At enrollment (≥37 weeks of gestation)

  4. Serum LBP Level

    Serum lipopolysaccharide-binding protein (LBP) concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.

    Time frame: At enrollment (≥37 weeks of gestation)

  5. Serum sCD14 Level

    Serum soluble CD14 (sCD14) concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.

    Time frame: At enrollment (≥37 weeks of gestation)

Secondary outcomes

  1. Serum TNF-alpha Level

    Serum tumor necrosis factor-alpha (TNF-α) concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.

    Time frame: At enrollment (≥37 weeks of gestation)

  2. Serum IL-6 Level

    Serum interleukin-6 (IL-6) concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.

    Time frame: At enrollment (≥37 weeks of gestation)

  3. Serum hs-CRP Level

    Serum high-sensitivity C-reactive protein (hs-CRP) concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.

    Time frame: At enrollment (≥37 weeks of gestation)

  4. Serum Vitamin D Receptor Level

    Serum vitamin D receptor (VDR) concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.

    Time frame: At enrollment (≥37 weeks of gestation)

  5. Serum 25-Hydroxyvitamin D Level

    Serum 25-hydroxyvitamin D \[25(OH)D\] concentration measured using a commercially available ELISA kit and compared between the excessive and recommended gestational weight gain groups.

    Time frame: At enrollment (≥37 weeks of gestation)

  6. Fasting Blood Glucose Level

    Fasting blood glucose concentration measured using routine biochemical laboratory methods and compared between the excessive and recommended gestational weight gain groups.

    Time frame: At enrollment (≥37 weeks of gestation)

  7. Fasting Serum Insulin Level

    Fasting serum insulin concentration measured using routine laboratory methods and compared between the excessive and recommended gestational weight gain groups.

    Time frame: At enrollment (≥37 weeks of gestation)

  8. HOMA-IR Index

    Insulin resistance assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated as fasting glucose (mg/dL) multiplied by fasting insulin (µIU/mL) divided by 405. HOMA-IR values will be compared between the excessive and recommended gestational weight gain groups.

    Time frame: At enrollment (≥37 weeks of gestation)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — After complatet the study i will be agree to share.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2026 to primary completion in Nov 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 16, 2026
StartActual
Apr 6, 2026
Primary completionActual
Nov 1, 2026
CompletionEst.
Jun 3, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940140
Responsible party
Dilara Ulger Ozbek (Dr, Cumhuriyet University) — Principal investigator
First posted
Nov 16, 2026
Start date
Apr 6, 2026
Primary completion
Nov 1, 2026
Completion
Jun 3, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

DILARA ÜLGER ÖZBEK, PhD
principal investigator · Cumhuriyet University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion